Gland Pharma Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹49.0K Cr
Base business (ex-Cenexi) revenue declined 8% YoY in Q3 FY'25 due to volume de-growth in key products but is expected to recover volumes in coming quarters. - U.S. EBITDA margins expected to improve beyond past levels of 33%-34%, reflecting better product mix and new product launches (Ravi Mitra, Page 15). - Base business excluding Cenexi showed strong EBITDA margin improvement to 39% from 34% YoY, driven by product mix and cost control (Page 7). - Cenexi expects positive EBITDA by full year FY 2026, with revenue targets beyond EUR 200 million, despite recent quarter challenges (Alain Kirchmeyer, Page 6). - New capacity additions at Cenexi (new ampoule and prefilled syringe lines) to boost production and support growth (Page 6). - Launch of 13 new molecules in the U.S.
From Gland Pharma Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,819
Market Cap
₹49.0K Cr
P/E Ratio
42.8
How does Gland Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare Gland Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Gland Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.7K Cr, net profit ₹367 Cr.
Full financials →📊 Revenue & Sales Performance
- →Base business (ex-Cenexi) revenue declined 8% YoY in Q3 FY'25 due to volume de-growth in key products but is expected to recover volumes in coming quarters.
- →U.S. sales strengthened with 13 new molecule launches, enhancing portfolio for growth.
- →Enoxa volumes are expected to increase, although higher Enoxa volumes may slightly reduce overall margins.
- →New launches (complex generics, RTUs) with higher gross margins (~65%) are being aggressively pushed to sustain/improve margins.
- →New auto injector line adding 100 million capacity expected to contribute mainly from end FY'27, with smaller volumes from FY'26.
- →Cenexi business expected to reach EBITDA breakeven by Q3 FY'26 with new high-speed lines and cost controls.
- →Focus on expanding presence in key RoW markets (top 5-6 countries) with aggressive partnerships and filings.
- →GLP-1 CDMO contracts anticipated to start generating revenue slowly from FY'26.
- →Biosimilar manufacturing capacity expansion planned to 15 KL to meet growing demand by FY'27-FY'28.
📈 Profitability & Margins
🏗️ Capital Expenditure Plans
- →Adding one more pen/auto injector assembly line this year, adding 100 million capacity; most of the capex already spent; commissioning expected by FY '28 (major volumes end FY '27).
- →Evaluating biosimilars capacity expansion (~15 KL), estimated capex $80-$100 million; process of project evaluation ongoing.
- →GLP-1 line investment mostly done; line to be installed within next 2 quarters; planning a greenfield project for next growth phase.
- →Cartridge capacity expansion: new cartridge line addition at Suite 9 in India in progress alongside existing line.
- →At Cenexi (France), installing new high-speed ampoule and prefilled syringe lines to improve capacity and capabilities.
- →Considering further capex for bulk cartridge production at Cenexi; current plans under evaluation.
- →Overall strategic focus includes inorganic expansion in India and potential M&A for high-value injectables.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
- →The current order book for the fourth quarter is approximately EUR 60 million, carrying over backlog from 2024. (Page 17)
- →Cenexi typically maintains a 3-month confirmed order horizon with customers. (Page 17)
- →There's a pipeline of RFPs being addressed, with recent validation batches for 2 products moving into commercial production in Q1. (Page 14)
- →Some contracts and shipments, such as the Saudi contract, have faced delays, with expected progress in Q4 or early next year. (Page 9)
- →Interest is seen in shifting RoW capacity from Cenexi's Europe site to India, though business discussions are ongoing. (Page 11)
- →For biosimilars and GLP-1 CDMO contracts, timelines indicate revenues starting from FY '26, with new capacities in evaluation. (Pages 11, 17)
Key Metrics
Frequently Asked Questions
What were Gland Pharma Ltd Q3 FY25 results?
Base business (ex-Cenexi) revenue declined 8% YoY in Q3 FY'25 due to volume de-growth in key products but is expected to recover volumes in coming quarters. - U.S. EBITDA margins expected to improve beyond past levels of 33%-34%, reflecting better product mix and new product launches (Ravi Mitra, Page 15). - Base business excluding Cenexi showed strong EBITDA margin improvement to 39% from 34% YoY, driven by product mix and cost control (Page 7). - Cenexi expects positive EBITDA by full year FY 2026, with revenue targets beyond EUR 200 million, despite recent quarter challenges (Alain Kirchmeyer, Page 6). - New capacity additions at Cenexi (new ampoule and prefilled syringe lines) to boost production and support growth (Page 6). - Launch of 13 new molecules in the U.S.
What is Gland Pharma Ltd share price analysis?
Gland Pharma Ltd currently shows a neutral. The stock trades at a P/E of 42.8 with a market cap of ₹48,998 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gland Pharma Ltd planning capital expenditure?
Adding one more pen/auto injector assembly line this year, adding 100 million capacity; most of the capex already spent; commissioning expected by FY '28 (major volumes end FY '27).
Keep Gland Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.